COMMUNICATION
|
doi:10.20944/preprints202212.0131.v1
Subject:
Medicine And Pharmacology,
Oncology And Oncogenics
Keywords:
rasburicase; anaphylaxis; re-administration; hematological malignancies; claims data
Online: 7 December 2022 (11:54:18 CET)